iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al.
Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL
Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myeloma
Six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses
Stephen J. Schuster
Responses to CAR T-Cell therapy still strong after one year in patients with refractory NHL